Arjuna HeartTM from Ayush Herbs, Inc.
Arjuna HeartTM is a cardio protective formula based on traditional Ayurvedic medicine. The principal herb is Terminalia arjuna along with Inula racemosa, magnesium, COQ10, B6 and folic acid.
Inula racemosa has been used extensively in heart disease. It reduced ECG signs of ischemia after exercise in patients with ischemic heart disease 9 therefore, reducing the patients need for gylceryl trinitrate. Another study indicated significant anti-anginal activity, lowering diastolic blood pressure, plasma Cortisol and catecholamines. 10
Vitamins pyridoxine (B6) and folate (B9) are included in Arjuna HeartTM as cofactors required for homocysteine metabolism. Clinical studies report lowered cardiovascular risk in women with the highest intake of folate and B6. 11
Magnesium is an essential mineral in cardiac pathology, reported to increase perfusion of the myocardium, prevent stroke, decrease cholesterol and hypertension.
COQ10 improves contractility to the cardiac muscle, prevents LDL oxidation therefore acting as an antioxidant. 12
Typical Dosage of Arjuna is 500mn of standardized extract: 1 capsule TID; safe to use in conjunction with other medication.
Arjuna HeartTM is best used for Angina, Cardiomyopathy, Congestive Heart Failure, myocardial infarction. It is effectively used in conjuction with the following products for conditions stated:
Guggal-Lip for raised cholesterol Carditone for hypertension
1 National Heart Foundation website: http://www.nhf.org.nz/index.asp?pageID=2145828139
2, 3, 11, 12 Appleton J., Birdsall T., Bone K et al. Alternative Medicine Review, Monographs Vol 1. Idaho, USA. Thorne Research, Inc.; 2002: 411-413, 357, 105
4, 5, 9 Bone K. Clinical Applications of Ayurvedic and Chinese Herbs: Monographs for the Western Herbal Practitioner 1st Ed., Queensland, Australia. Phytotherapy Press; 1996: 132, 133, 120
6, 8 Ayush Herbs, Inc. website: http://www.ayush.com/common/news/store_news.asp?task 7 Bharani A, Ganguly A, Bhargave KD. Salutary Effect of Terminalia Arjuna in Patients with Severe refractory Heart Failure. Int J Cardiol 1995; 49: 191-199
10 Dwivedi, S et al: Int Crude Drug Res. 27;217 (1989)
This information provided by: